DOP2012000044A - Anticuerpos contra el extodominio de erbb3 y usos de los mismos - Google Patents

Anticuerpos contra el extodominio de erbb3 y usos de los mismos

Info

Publication number
DOP2012000044A
DOP2012000044A DO2012000044A DO2012000044A DOP2012000044A DO P2012000044 A DOP2012000044 A DO P2012000044A DO 2012000044 A DO2012000044 A DO 2012000044A DO 2012000044 A DO2012000044 A DO 2012000044A DO P2012000044 A DOP2012000044 A DO P2012000044A
Authority
DO
Dominican Republic
Prior art keywords
erbb3
same
antibodies
receiver
antigen
Prior art date
Application number
DO2012000044A
Other languages
English (en)
Spanish (es)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000044(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of DOP2012000044A publication Critical patent/DOP2012000044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2012000044A 2009-08-21 2012-02-20 Anticuerpos contra el extodominio de erbb3 y usos de los mismos DOP2012000044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
DOP2012000044A true DOP2012000044A (es) 2012-06-30

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000044A DOP2012000044A (es) 2009-08-21 2012-02-20 Anticuerpos contra el extodominio de erbb3 y usos de los mismos

Country Status (21)

Country Link
EP (1) EP2467164A2 (enrdf_load_stackoverflow)
JP (1) JP5752687B2 (enrdf_load_stackoverflow)
KR (1) KR20120059568A (enrdf_load_stackoverflow)
CN (1) CN103002912A (enrdf_load_stackoverflow)
AU (1) AU2010284018C1 (enrdf_load_stackoverflow)
BR (1) BR112012003809A2 (enrdf_load_stackoverflow)
CA (1) CA2771744A1 (enrdf_load_stackoverflow)
CR (1) CR20120108A (enrdf_load_stackoverflow)
DO (1) DOP2012000044A (enrdf_load_stackoverflow)
EA (1) EA201200195A1 (enrdf_load_stackoverflow)
EC (1) ECSP12011740A (enrdf_load_stackoverflow)
IL (1) IL218097A0 (enrdf_load_stackoverflow)
IN (1) IN2012DN01518A (enrdf_load_stackoverflow)
MA (1) MA33582B1 (enrdf_load_stackoverflow)
MX (1) MX336091B (enrdf_load_stackoverflow)
NI (1) NI201200027A (enrdf_load_stackoverflow)
PE (1) PE20121585A1 (enrdf_load_stackoverflow)
SG (1) SG178509A1 (enrdf_load_stackoverflow)
TN (1) TN2012000057A1 (enrdf_load_stackoverflow)
WO (1) WO2011022727A2 (enrdf_load_stackoverflow)
ZA (1) ZA201201195B (enrdf_load_stackoverflow)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EP3351558B1 (en) * 2009-11-13 2020-03-11 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
RU2560583C2 (ru) 2009-12-22 2015-08-20 Рош Гликарт Аг Антитела к her3 и их применения
CN102858335B (zh) 2010-03-11 2015-04-15 梅里麦克制药股份有限公司 Erbb3抑制剂在三阴性乳腺癌和基底样乳腺癌治疗中的用途
CA2795799C (en) 2010-04-09 2018-09-25 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
KR101517320B1 (ko) * 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
CA2849508C (en) 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
CN108753942A (zh) 2011-10-06 2018-11-06 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
EP2788377B1 (en) * 2011-11-09 2019-01-23 The UAB Research Foundation Her3 antibodies and uses thereof
TW201328706A (zh) 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
MD3365373T2 (ro) 2015-10-23 2021-08-31 Merus Nv Molecule de legare care inhibă dezvoltarea cancerului
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
EA201992522A1 (ru) 2017-05-17 2020-04-22 Мерус Н.В. КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
CA3072267A1 (en) 2017-08-09 2019-02-14 University Of Saskatchewan Her3 binding agents and uses thereof
EA202090215A1 (ru) 2017-08-09 2020-07-01 Мерус Н.В. АНТИТЕЛА, СВЯЗЫВАЮЩИЕ EGFR И cMET
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
CA3196940A1 (en) * 2020-10-14 2022-04-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
CA3199259A1 (en) * 2020-11-20 2022-05-27 Dale L Ludwig Her3 radioimmunotherapy for the treatment of solid cancers
IL309337A (en) * 2021-06-15 2024-02-01 Beijing Sinotau Bio Pharmaceuticals Tech Co Ltd Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and uses thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania

Also Published As

Publication number Publication date
NI201200027A (es) 2013-01-29
CR20120108A (es) 2012-06-05
IL218097A0 (en) 2012-04-30
EA201200195A1 (ru) 2012-12-28
MA33582B1 (fr) 2012-09-01
BR112012003809A2 (pt) 2019-09-24
SG178509A1 (en) 2012-04-27
TN2012000057A1 (en) 2013-09-19
ECSP12011740A (es) 2013-02-28
AU2010284018C1 (en) 2015-10-15
WO2011022727A3 (en) 2013-06-27
MX2012002172A (es) 2012-05-29
JP2013506622A (ja) 2013-02-28
KR20120059568A (ko) 2012-06-08
WO2011022727A2 (en) 2011-02-24
JP5752687B2 (ja) 2015-07-22
EP2467164A2 (en) 2012-06-27
MX336091B (es) 2016-01-08
CN103002912A (zh) 2013-03-27
PE20121585A1 (es) 2012-11-29
ZA201201195B (en) 2015-07-29
AU2010284018A1 (en) 2012-03-22
CA2771744A1 (en) 2011-02-24
AU2010284018B2 (en) 2014-06-05
IN2012DN01518A (enrdf_load_stackoverflow) 2015-06-05

Similar Documents

Publication Publication Date Title
DOP2012000044A (es) Anticuerpos contra el extodominio de erbb3 y usos de los mismos
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
MX2017003596A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
MX2018005674A (es) Receptores de antigenos quimericos dirigidos a her2.
ECSP099637A (es) Anticuerpos contra el erbb3 y los usos de los mismos
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CL2018002380A1 (es) Divisional de la solicitud 2433-2012 por anticuerpos reactivos con b7-h3, fragmentos inmunológicamente activos de los mismos y sus usos.
EA201491573A1 (ru) Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения
CL2016002547A1 (es) Anticuerpos contra her2 biespecíficos
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX377716B (es) Moduladores de aplnr y usos de estos.
MX377710B (es) Anticuerpos monoclonales contra bcma.
UY34813A (es) Proteínas de unión a antígeno dirigidas contra el receptor st2
DOP2015000269A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
CR20150493A (es) Composiciones de amri contra el componente c5 del complemento y métodos para su uso
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
UY37026A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
MX378368B (es) Receptores de antigeno y usos de los mismos.
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
TR201905272T4 (tr) İmmünojenik bileşim.
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CL2017001445A1 (es) Fibras de polipropileno mejoradas, métodos para producirlas y sus usos para la producción de productos de fibrocemento.